Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
05/2003
05/27/2003US6569452 Camptothecin analogue dispersed or solubilized in a semi-solid matrix of a polyethylene glycol; irinotecan hydrochloride
05/27/2003US6569450 Lipid-conjugated polyamide compounds and related compositions and methods thereof
05/27/2003US6569449 For treatment of eating disorders, narcotic dependence and alcoholism.
05/27/2003US6569448 Method for preventing crystal formation in a dispersion of a liquid in a matrix
05/27/2003US6569443 Topical treatment or prevention of ocular infections
05/27/2003US6569441 Therapeutic inhibitor of vascular smooth muscle cells
05/27/2003US6569439 Process for making personal care compositions comprising titanium dioxide and personal care compositions made by the process
05/27/2003US6569424 A probiotic formulation of Escherichia coli strain BU-230-98 ATCC Deposit No. 20226 (DSM 12799); containing at least one volatile fraction (VF) of a plant extract
05/27/2003US6569416 Compositions containing synthetic soil-extract materials and medicaments based thereon
05/27/2003US6569406 Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
05/27/2003US6569405 Atomizing solution through an orifice into a gas such that said liquid evaporates thereby forming a powder of hollow microcapsules
05/27/2003US6569363 Apparatus and methods for forming patterned soft gelatin capsules
05/27/2003US6569292 Drug delivery system which effects the controlled release of a medicinally active ingredient to a targeted site
05/27/2003US6569195 Stent coating
05/27/2003US6569152 Sustained release delivery systems for solutes
05/27/2003US6568398 Treating a wound with a wound healing agent comprising a granular astringent hemostatic agent micro-encapsulated with a biopolymer, observing the cover layer of microcapsules remain white, then removing the microcapsules
05/27/2003CA2387361C Crystal form 0 and form ii of clarithromycin and uses thereof
05/27/2003CA2387356C Crystal form 0 and form i of clarithromycin and uses thereof
05/27/2003CA2386527C Crystal form i of clarithromycin
05/27/2003CA2321829C Topical composition containing human epidermal growth factor
05/27/2003CA2310960C Phosphate-binding polymers for oral administration
05/27/2003CA2277274C Crystal form 0 of clarithromycin
05/27/2003CA2199747C 2',5' phosphorothioate/phosphodiester oligoadenylates and antiviral uses thereof
05/27/2003CA2174072C Hydrogel-forming, self-solvating absorbable polyester block copolymers, and methods for use thereof
05/27/2003CA2110119C Antiinflammatory and analgesic gel preparation
05/27/2003CA2032201C Sunscreen compositions
05/22/2003WO2003042344A2 Apo2 ligand/trail formulations
05/22/2003WO2003042300A1 Method for preparing gels
05/22/2003WO2003042251A1 Chitosan compositions
05/22/2003WO2003042248A1 Preparation method of solvent-free water-dispersible hydroxypropyl methyl cellulose phthalate nanoparticle
05/22/2003WO2003042240A2 Polypeptides of pseudomonas aeruginosa
05/22/2003WO2003042113A1 Production of cell suspensions
05/22/2003WO2003041757A2 Catheter injectable depot compositions and uses thereof
05/22/2003WO2003041742A1 Nutraceutical composition
05/22/2003WO2003041729A1 Ptp1b inhibitors and ligands
05/22/2003WO2003041720A1 Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof
05/22/2003WO2003041705A1 Oral dosage form of a sulfonamide prodrug such as parecoxib
05/22/2003WO2003041702A1 Production of pure stereoisomers of tricyclo[5.2.1.02.6]-dec-9-yl xanthogenate and medicaments therefrom
05/22/2003WO2003041700A1 Storage stable thyroxine active drug formulations
05/22/2003WO2003041699A1 Storage stable thyroxine active drug formulations and methods for their production
05/22/2003WO2003041698A1 Amino acid-containing tablets quickly disintegrating in the oral cavity and process for producing the same
05/22/2003WO2003041696A1 Methods and compositions for use of (s)-bisoprolol
05/22/2003WO2003041693A1 Delivery of diazepam through an inhalation route
05/22/2003WO2003041692A1 Extended release compositions comprising as active compound venlafaxine hydrochloride
05/22/2003WO2003041691A1 Solid formulation producing carbon dioxide when contacting liquid acid and a method of preparing the same
05/22/2003WO2003041690A2 Three-dimensional suspension printing of dosage forms
05/22/2003WO2003041689A1 Biocompatible polymer blends and uses thereof
05/22/2003WO2003041688A1 Methods for treatment of inflammatory diseases
05/22/2003WO2003041687A2 Method for producing stable solutions of phenolic substances and resulting solutions
05/22/2003WO2003041686A2 Improved therapy for topical diseases
05/22/2003WO2003041685A1 Injectable depot composition
05/22/2003WO2003041684A2 Injectable depot compositions and uses thereof
05/22/2003WO2003041683A2 Orodispersible tablets containing fexofenadine
05/22/2003WO2003041682A2 Lipid carrier compositions and methods for improved drug retention
05/22/2003WO2003041681A2 Lipid carrier compositions with enhanced blood stability
05/22/2003WO2003041680A1 Topical compositions containing enzymes stabilized with inhibitors
05/22/2003WO2003041678A1 Carotenoid composition and method for protecting skin
05/22/2003WO2003041656A2 Soluble drug extended release system
05/22/2003WO2003041651A2 Allatoin-containing skin cream
05/22/2003WO2003041648A2 High-concentration lidocaine compositions and methods for their preparation
05/22/2003WO2003041638A2 Suppository base
05/22/2003WO2003041637A2 Lyophilized monoclonal antibody compositions
05/22/2003WO2003041632A2 Eutectic-based self-nanoemulsified drug delivery system
05/22/2003WO2003041509A1 Microcapsules and oral compositions containing the same
05/22/2003WO2003041500A1 Topical formulations of natamycin/pimaricin
05/22/2003WO2003020763A3 Soluble t cell receptor
05/22/2003WO2003020253A3 Pharmaceutical compositions for the treatment of asthma
05/22/2003WO2003000299B1 Laxative preparation
05/22/2003WO2002097116A3 Delivery system for nucleic acids
05/22/2003WO2002085431A3 Method of delivering liquid through cerebral spinal pathway
05/22/2003WO2002076425A3 Manufacturing dissolvable dosage forms
05/22/2003WO2002076390A3 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists
05/22/2003WO2002053186A3 Fluticasone suspension formulation, spray pattern method, and nasal spray apparatus
05/22/2003WO2002045685A3 Cristallizable/non crystallizable polymer composites
05/22/2003WO2002041844A9 Chemotherapeutic composition using nanocrystalline calcium phosphate paste
05/22/2003WO2002024146A3 Methods of decreasing or preventing pain using spicamycin derivatives
05/22/2003WO2001045675A8 Valve for osmotic devices
05/22/2003US20030097121 Implantable fluid delivery apparatuses and implantable electrode
05/22/2003US20030097120 Bioactive surface modifiers for polymers and articles made therefrom
05/22/2003US20030097092 Devices, systems and methods for patient infusion
05/22/2003US20030097011 Novel carbamate-based cationic lipids
05/22/2003US20030096921 Elastomer comprising poly(alkylene oxide) groups present as alkoxy-terminated grafts of polysiloxane units and linked to polysiloxane units by silicon-carbon bonds, vinyl functional component is crosslinked in presence of peroxide catalyst
05/22/2003US20030096920 Drug delivery
05/22/2003US20030096879 Gels of hyaluronic acid cross-linked with bi-functional l-aminoacids or l-aminoesters or mixtures thereof
05/22/2003US20030096874 For prophylaxis and therapy of respiratory diseases asthma, chronic obstructive pulmonary disease (COPD), respiratory tract infection or upper respiratory tract disease
05/22/2003US20030096873 Administering therapeutically effective amount of (+)-bupropion or a pharmaceutically acceptable salt thereof, substantially free of its (-)-stereoisomer for therapy of pain
05/22/2003US20030096872 Acetaminophen compositions
05/22/2003US20030096868 Sertraline oral concentrate
05/22/2003US20030096861 Producing an aqueous solution of bismuth sodium tartrate; extracting a magma of bismuth sodium tartrate from aqueous solution and dissolving magma into a salting-in mixture to form semitransparent colloidal solution
05/22/2003US20030096850 Treating infections by administration of oxazolidinones
05/22/2003US20030096845 Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
05/22/2003US20030096840 Granule formulation
05/22/2003US20030096837 Clopidogrel bisulfate tablet formulation
05/22/2003US20030096834 Pharmaceutical compositions
05/22/2003US20030096822 Comprises moxidectin, praziquantel, benzyl alcohol, ethanol, colloidal silicon dioxide, surfactant, and oil; veterinary medicine
05/22/2003US20030096799 Novel 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity
05/22/2003US20030096792 Compositions comprising sibutramine metabolites in combination with phosphodiesterase inhibitors
05/22/2003US20030096791 Taste masking of highly water-soluble drugs
05/22/2003US20030096774 Compositions of nucleic acids and cationic aminoglycosides and methods of using and preparing the same
05/22/2003US20030096769 Genetic molecules capable of modulating growth factor interaction with its receptor on epidermal keratinocytes
1 ... 2137 2138 2139 2140 2141 2142 2143 2144 2145 2146 2147 2148 2149 2150 2151 2152 2153 2154 2155 2156 2157 ... 2991